ProfileGDS5678 / 1422066_x_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 59% 57% 58% 54% 59% 60% 66% 57% 56% 57% 58% 57% 58% 60% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.5739659
GSM967853U87-EV human glioblastoma xenograft - Control 23.4734357
GSM967854U87-EV human glioblastoma xenograft - Control 33.4824158
GSM967855U87-EV human glioblastoma xenograft - Control 43.2768254
GSM967856U87-EV human glioblastoma xenograft - Control 53.4820259
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.6677160
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 24.039566
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.4688857
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.3878656
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.4303157
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.4809758
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.4030857
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.5178358
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.5621160